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Abstract
Background: The HIV1 protein Vpr assembles with and acts through an ubiquitin ligase complex that includes DDB1 and
cullin 4 (CRL4) to cause G2 cell cycle arrest and to promote degradation of both uracil DNA glycosylase 2 (UNG2) and single-
strand selective mono-functional uracil DNA glycosylase 1 (SMUG1). DCAF1, an adaptor protein, is required for Vpr-
mediated G2 arrest through the ubiquitin ligase complex. In work described here, we used UNG2 as a model substrate to
study how Vpr acts through the ubiquitin ligase complex. We examined whether DCAF1 is essential for Vpr-mediated
degradation of UNG2 and SMUG1. We further investigated whether Vpr is required for recruiting substrates to the ubiquitin
ligase or acts to enhance its function and whether this parallels Vpr-mediated G2 arrest.
Methodology/Principal Findings: We found that DCAF1 plays an important role in Vpr-independent UNG2 and SMUG1
depletion. UNG2 assembled with the ubiquitin ligase complex in the absence of Vpr, but Vpr enhanced this interaction.
Further, Vpr-mediated enhancement of UNG2 degradation correlated with low Vpr expression levels. Vpr concentrations
exceeding a threshold blocked UNG2 depletion and enhanced its accumulation in the cell nucleus. A similar dose-
dependent trend was seen for Vpr-mediated cell cycle arrest.
Conclusions/Significance: This work identifies UNG2 and SMUG1 as novel targets for CRL4
DCAF1-mediated degradation. It
further shows that Vpr enhances rather than enables the interaction between UNG2 and the ubiquitin ligase. Vpr augments
CRL4
DCAF1-mediated UNG2 degradation at low concentrations but antagonizes it at high concentrations, allowing nuclear
accumulation of UNG2. Further, the protein that is targeted to cause G2 arrest behaves much like UNG2. Our findings
provide the basis for determining whether the CRL4
DCAF1 complex is alone responsible for cell cycle-dependent UNG2
turnover and will also aid in establishing conditions necessary for the identification of additional targets of Vpr-enhanced
degradation.
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Introduction
HIV1 Vpr and its HIV2 and SIV counterparts Vpr and Vpx
rely on an ubiquitin ligase, characterized by the components
DCAF1, DDB1 and Cullin 4, to execute cellular functions. This
complex plays a crucial role in HIV1- and HIV2 Vpr-mediated
G2 cell cycle arrest [1,2,3,4,5,6,7]. The same ubiquitin ligase
complex is also recruited by the closely related HIV2- and SIVSM
Vpx proteins to defeat an antiviral factor that blocks efficient
reverse transcription in cells of the monocytic lineage [8,9,10,11].
Each of these functions can be hindered by application of
proteasome inhibitors.
HIV1 Vpr is a 96 amino acid protein that is incorporated into
virions specifically, in small quantities, through a physical
interaction with the p6 portion of the Gag polyprotein [12].
Expression of Vpr in dividing cells can block progression of the cell
cycle in the G2 phase after most or all of the cellular chromatin has
been replicated [13,14]. This block establishes intracellular
conditions that are similar to those encountered after DNA
damage [15]. How HIV benefits from this block remains
unresolved, although G2, when chromatin is fully assembled and
cells are not dividing, may provide an optimal environment for
virus production [16]. Expression of HIV2 and SIVSM Vpr also
results in G2 arrest albeit in a lower percentage of cells than in
HIV1 Vpr-expressing cultures. The lower level of arrest may be
due to lower levels of Vpr expression [17], different interactions
with cellular partners or both.
While it is clear that HIV1 Vpr and its HIV2 and SIVSM
counterparts require ubiquitin ligase for at least some of their
functions, including induction of cell cycle arrest, the mechanism
by which Vpr targets host proteins for degradation has not been
established. Specifically, it has not been determined whether Vpr
recruits new targets to the ubiquitin ligase complex or enhances
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targeted. The only established substrates for Vpr-enhanced
degradation in the presence of the CRL4 complex are the uracil
DNA glycosylases, UNG2 and SMUG1. These two enzymes act to
hydrolyze the N-glycosylic bond between the uracil base and
deoxyribose in the context of DNA and thus initiate base excision
repair. Proteasomal degradation of both UNG2 and SMUG1 is
accelerated in the presence of HIV1 Vpr [18]. Neither of these two
proteins has been linked to Vpr-mediated G2 arrest or shown to be
the factor that blocks reverse transcription in macrophages. UNG2
has however been shown to interfere with HIV1 infection in the
presence of APOBEC3G unless Vpr is present to diminish UNG2
levels [6]. Curiously, other labs showed that UNG2 is required for
efficient HIV1 replication and was recruited into virions by
integrase or by Vpr [19,20]. Mansky et al. hypothesized that
UNG2, recruited into virions by Vpr, could help to protect viral
DNA from dUTP misincorporation during reverse transcription in
macrophages or from the effects of cytidine deamination [21].
Indeed virus expressing a Vpr mutant that lacks the capacity to
recruit UNG2 had a four-fold higher G-to-A mutation rate than
wild-type virus [21]. More recently, Yan et al. showed that during
infections HIV DNA is heavily uracilated in human immune cells
[22]. This work further demonstrated that uracilation helps to
shield proviruses from the destructive effects of auto-integration.
Norman and colleagues showed that UNG2 plays an important
role in Vpr-mediated up-regulation of cellular NK cell ligands
[23], another recently described Vpr function [24,25]. Still other
work showed that UNG2 has no significant impact on HIV1
replication [26,27].
UNG2, regardless of its role in HIV infection, is targeted for
accelerated proteasomal degradation in the presence of Vpr [18]
and therefore serves as a useful model for understanding how Vpr
marks proteins for destruction by the CRL4 ubiquitin ligase
complex. In work described here we used UNG2 as a model target
for Vpr-directed protein degradation. We extended findings from
other labs by showing that Vpr-directed UNG2 degradation, like
Vpr-mediated G2 arrest, requires DCAF1 in addition to DDB1 and
Cul4 [6,28]. Importantly, we determined that Vpr is not required
for basal levels of CRL4
DCAF1-mediated UNG2 degradation or for
theassociation of UNG2 withthis complexbutrather Vprenhances
this process. This is the first evidence to support a model in which
Vpr augments the normal turnover of CRL4
DCAF1 substrates. We
further found that Vpr-mediated accentuation of UNG2 turnover is
blocked when a Vprexpression threshold is exceeded. The interplay
between Vpr levels and UNG2 degradation paralleled the levels of
Vpr-mediated G2 cell cycle arrest that we observed. The as yet
unidentified cellular factor that is ubiquitinated to cause G2 arrest
may thus have interactions with Vpr and the ubiquitin ligase
complex that are similar to those of UNG2. This mechanistic
explanation of Vpr-mediated degradation will aid future work to
identify proteins that are more efficiently degraded in the presence
of Vpr and could shed new light on how UNG2 is depleted during
normal progression of the cell cycle.
Results
CRL4
DCAF1 physically engages and degrades UNG2
Earlier work that identified the CRL4 ubiquitin ligase complex as
a functional cellular partner for HIV1 Vpr did not address the role
for Vpr in this complex. Specifically, does HIV1 Vpr act as adaptor
to expand the specificity of the ubiquitin ligase complex or to
enhance the interaction with a protein that is already a target of the
complex? To address this question, we selected UNG2, one of only
two known targets of Vpr-mediated degradation, as our model
substrate. Schro ¨felbauer et al. showed that UNG2 is ubiquitinated
and degraded in a Vpr-dependent manner and that this process
relies on the CRL4 ubiquitin ligase complex [6]. This work did not
however address whether DCAF1 is required for UNG2 degrada-
tion as it is for Vpr-mediated G2 cell cycle arrest [6]. To establish
UNG2 as a model for Vpr-mediated degradation, we needed to
determine whether DCAF1 is required for Vpr-mediated UNG2
degradation as it is for Vpr-mediated G2 cell cycle arrest.
If DCAF1 is required for Vpr-mediated UNG2 depletion, then
removal of DCAF1 should increase UNG2 levels in the presence
of Vpr. To test this we measured levels of UNG2 in cultures
transfected with an expression vector for UNG2 with two HA
epitope tags at the carboxy-terminus (UNG2–2HA) and either
DCAF1-directed shRNA or a non-targeting plasmid in the
presence or absence of HIV1 Vpr. Surprisingly, we observed that
UNG2 levels increased when DCAF1 expression was perturbed
both in the presence and in the absence of HIV1 Vpr (Figure 1A).
This result led us to hypothesize that CRL4
DCAF1 also mediates
turnover of UNG2 in the absence of Vpr, albeit at a lower level.
To confirm that UNG2 is degraded by CRL4
DCAF1, we perturbed
a second component of the complex, DDB1, either by reducing its
expression using a DDB1-specific shRNA or by over-expressing it
from a DDB1-encoding plasmid and measured endogenous levels
of UNG2 (Figure 1B). We have demonstrated previously that
either over-expressing or reducing expression of DDB1 blocks
Vpr-mediated cell cycle arrest [1]. In this experiment, we detected
higher endogenous UNG2 levels in cells with either reduced
DDB1 expression or DDB1 over-expression compared to cells that
express wild-type DDB1 levels. This shows for the first time that
CRL4
DCAF1 determines steady state levels of UNG2. Our
observation that UNG2 is turned over by CRL4
DCAF1 is
particularly significant because only one other substrate, Merlin,
has been identified for DCAF1 in the context of the CRL4 [29].
Further, our findings show that DCAF1 is required for Vpr-
mediated enhancement of UNG2 degradation as it is for Vpr-
mediated G2 cell cycle arrest.
Schro ¨felbauer et al. also showed that another uracil DNA
glycosylase, SMUG1, is depleted in a Vpr-dependent manner
[18]. We reasoned that Vpr-mediated enhancement of normal
CRL4
DCAF1 substrates may be a general mechanism and therefore
also tested the levels of SMUG1 in the presence or absence of
DCAF1 and DDB1. We found that SMUG1 levels like those of
UNG2 increase when DCAF1 or DDB1 is depleted both in the
presence or absence of Vpr (Figure 1C and D). SMUG1 is thus the
third target for this complex and the second to be degraded more
efficiently by this complex in the presence of Vpr.
If CRL4
DCAF1 targets UNG2 for degradation, then these
proteins must assemble within the same complex. We immuno-
precipitated DCAF1 from cells co-transfected with UNG2–2HA
and FLAG–HA–DCAF1 to test whether DCAF1 and UNG2
assemble and can therefore be co-isolated. Using beads coated
with FLAG epitope tag-specific antibody, we were able to co-
isolate UNG2–2HA from lysates of cells expressing FLAG–HA–
DCAF1 but not from those of cells expressing untagged DCAF1,
our negative control (Figure 1E). This physical association further
supports a model in which UNG2 associates with the ubiquitin
ligase complex through DCAF1 like Merlin and the target that is
responsible for Vpr-mediated G2 cell cycle arrest.
HIV1 Vpr increases UNG2 degradation by enhancing the
interaction between UNG2 and the ubiquitin ligase
complex
Our observation that UNG2 and SMUG1 are targets for the
CRL4
DCAF1 complex in the absence of Vpr compelled us to
HIV1 Vpr Enhances Constitutive UNG2 Turnover
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30939Figure 1. CRL4
DCAF1 is involved in constitutive turnover of UNG2 and SMUG1. Cultures of 293T HEK cells were transfected with 1 mgo f
UNG2–2HA expression vector, together with 2 mg of empty vector or 2 mg of an expression vector for DCAF1-directed shRNA and additional empty
vector (1 mg) or HIV1 FLAG–Vpr expression vector (1 mg). 48 hours after transfection cell lysates were harvested and tested for expression of UNG2–
2HA, HIV1 FLAG–Vpr, endogenous DCAF1 and b-actin by immunoblotting (A). 293T HEK cells were transfected with empty vector (4 mg), or
expression vector for DDB1 (4 mg) or DDB1-directed shRNA (4 mg) as indicated. Fourty-eight hours after transfection cell lysates were prepared and
tested for expression of endogenous UNG2, DDB1, and a-tubulin by immunoblotting (B). Cultures of 293T HEK cells were transfected with SMUG1-
3HA expression vector (1 mg), together with empty vector (2 mg) or an expression vector for DCAF1-directed shRNA (2 mg) and additional empty
vector (1 mg) or HIV1 FLAG–Vpr expression vector (1 mg). 48 hours after transfection cell lysates were harvested and tested for expression of SMUG1–
3HA, HIV1 FLAG–Vpr, DCAF1 and b-actin by immunoblotting (C). 293T HEK cells were transfected with empty vector (1 mg) or SMUG1–3HA expression
vector (1 mg) together with additional empty vector (3 mg) expression vectors for DDB1 (3 mg) or DDB1-directed shRNA (3 mg) as indicated. 48 hours
after transfection cell lysates were prepared and tested for expression of SMUG1-3HA, DDB1, and b-actin by immunoblotting (D). 293T HEK cells were
transfected with UNG2–2HA expression vector, together with empty vector or an expression vector for untagged DCAF1 or transfected with FLAG–
HA–DCAF1 expression vector, together with empty vector or an expression vector for UNG2–2HA. After 48 hours, the cells were lysed and the cleared
lysates were incubated with anti-FLAG agarose beads. The bound proteins were eluted with FLAG peptide. The eluted proteins and pre-
immunoprecipitation samples were characterized by immunoblotting with HA-specific antibody (E).
doi:10.1371/journal.pone.0030939.g001
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recruit new substrates to DCAF1, Vpr enhances the capacity of
CRL4
DCAF1 to target its endogenous substrates. Hrecka et al. first
raised the possibility that Vpr may be stimulating ubiquitin ligase
function through DDA1 [4], but direct interaction between Vpr
and DDA1 has not been established. Vpr has however been shown
to physically engage both UNG2 and DCAF1 in separate yeast
two-hybrid experiments [7,19]. We therefore reasoned that Vpr
could act to enhance the interaction between UNG2 and the
ubiquitin ligase complex. If this is the case, then expression of
HIV1 Vpr should allow more efficient isolation of DCAF1 with
UNG2. To test this possibility we immunoprecipitated HA-tagged
UNG2, using HA-specific, antibody-coated beads, from cells
transfected with expression vector encoding HIV1 FLAG–Vpr or
an empty control vector (Figure 2). Of note, we added Vpr at a
level that produces strong UNG2 depletion because that is where
we expected Vpr to enhance the interaction between UNG2 and
the ubiquitin ligase complex. We therefore treated the cultures
with the proteasome inhibitor MG132 for 8 hours prior to
harvesting the cell lysates in an effort to increase UNG2 levels in
the presence of Vpr. Immunobloting of the isolated proteins
revealed that we co-isolated ubiquitin ligase components from
both transfection types, however we co-isolated more of these
proteins relative to UNG2 in the presence of Vpr. This of course
suggests that Vpr enhances the interaction between UNG2 and
the ubiquitin ligase complex.
UNG2 is not degraded when Vpr is expressed at high
levels
UNG2 depletion was incomplete in our initial experiments and
appeared to be less pronounced than the levels shown in work by
Schroefelbauer et al. We reasoned that if Vpr acts as an adaptor
between UNG2 and the ubiquitin ligase complex, then adding
Vpr should enhance degradation of UNG2. This enhancement
should plateau if, for example, Vpr is modifying the binding
surface on one partner to allow the second to bind. Vpr could
however interfere with recruitment of UNG2 to the ubiquitin
ligase complex if high concentrations are able to saturate binding
sites on both UNG2 and DCAF1. We thus tested the impact of
expressing a range of Vpr levels on UNG2 degradation. The
quantities of transfected DNA were held constant with empty
expression vector. Western blotting for endogenous UNG2 in
whole-cell lysates harvested 24 hours after transfection revealed
two phases (Figure 3A and B). The first phase showed an increase
in UNG2 depletion with increasing Vpr expression. As Vpr levels
increased further, UNG2 depletion decreased. As a control, we
measured UNG1 levels. We found these to be relatively constant,
but increasing slightly with low levels of Vpr expression. While the
effects of Vpr on UNG2 levels appear modest, it is important to
note that this experiment examines total levels of endogenous
UNG2 in both Vpr-expressing cells as well as non-transfected cells.
Significantly, this is the first study to show this bi-phasic pattern of
Vpr-mediated degradation with endogenous UNG2.
The two phases of UNG2 expression are more pronounced in
cells co-transfected with constant quantities of UNG2 expression
vector and increasing quantities of HIV1 Vpr expression vector
(Figure 3C and D). This experiment focused on transfected cells,
and thus eliminated the background of UNG2 from cells not
transfected with Vpr. Importantly, these results confirm that
exogenously-expressed UNG2 recapitulates the effects of Vpr on
endogenous UNG2 and supports previous studies using exogenous
UNG2. The decrease of UNG2 levels, followed by an increase
suggests that as Vpr expression surpasses a threshold level, it can
no longer promote the interaction between DCAF1 and UNG2.
Since Vpr binds to both UNG2, the substrate, and to the ubiquitin
ligase complex, through DCAF1, our observation is consistent
with a model in which Vpr engages both UNG2 and the ubiquitin
ligase complex. At high expression levels Vpr interferes with the
assembly of UNG2 with the ubiquitin ligase by saturating binding
sites on both UNG2 and DCAF1.
Cellular UNG2 levels have been linked to the cell cycle
[30,31,32,33] and could be influenced by overall cell health. We
thus tested whether these factors play a role in the dose
dependence of Vpr-regulated UNG2 degradation. Schrofelbauer
et al. demonstrated that VprW54R, which does not assemble
efficiently with UNG2 but causes G2 arrest, fails to cause efficient
UNG2 depletion [18]. This observation showed that Vpr can
accentuate UNG2 depletion beyond levels caused by G2 arrest.
We extended these studies by determining whether the concen-
tration-dependent pattern of Vpr-mediated UNG2 depletion
could be achieved in the absence of G2 arrest. We tested the
HIV1 Vpr mutant, R90K, which has been shown to assemble with
UNG2 but yet not trigger G2 arrest [34,35] or apoptosis [35].
VprR90K like its wild-type counterpart mediated UNG2 deple-
tion at low concentrations, but failed to deplete at higher
concentrations (Figure 3E and F). In order to exclude the
possibility that Vpr-mediated cell death could be influencing our
results, we retained all cells from all of our cultures including any
in the media or PBS used for cell washing. Half of each culture was
reserved for western blot analysis and the other half for cell
viability analysis. Propidium iodide staining of unfixed cells
revealed that 48 hours after transfection, all cultures, regardless
of whether they were transfected with low or high quantities of
VprR90K (Figure 3E and F) or wild-type Vpr (Figure 3G and H),
contained equivalent quantities of necrotic cells (Figure S1A and
B). The percentage of dead cells varied by no more than two-fold
in each sample set while UNG2 was depleted over 25- and 40-fold
in the VprR90K and wild-type Vpr samples respectively. We also
transfected a separate set of cultures with a wider range of
VprR90K and wild-type Vpr concentrations together with a small
quantity of GFP expression vector. This allowed us to compare the
fraction of necrotic cells in transfected and untransfected cell
Figure 2. HIV1 Vpr enhances the interaction between UNG2
and the CRL4
DCAF1 ubiquitin ligase complex. 293T HEK cells were
transfected with either UNG2–myc (5 mg, lanes 1 and 4), 5 mg of UNG2–
2HA expression vector (lanes 2,3 5 and 6), together with empty vector
or expression vector for HIV1 FLAG–Vpr (1.25 mg, lanes 3 and 6). At
48 hours post-transfection, cells were lysed and the lysates were
incubated with HA-specific antibody linked to agarose beads. The
bound proteins were eluted with HA peptide. The eluted proteins and
pre-immunoprecipitation samples were characterized by immunoblot-
ting with antibodies specific for DCAF1, DDB1, the HA epitope tag or
the FLAG epitope tag.
doi:10.1371/journal.pone.0030939.g002
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30939Figure 3. HIV1 Vpr-mediated UNG2 degradation is dose-dependent. 293T HEK cells were transfected with empty vector or increasing
amounts of HIV1 FLAG–Vpr expression vector as indicated. 24 hours later the cells were lysed and the expression levels of UNG2, UNG1, HIV1 FLAG–
Vpr and b-actin were determined by immunoblotting (A). Quantitation of relative UNG1/2 degradation for Figure 3A was plotted (B). 293T HEK cells
were transfected with 1 mg of UNG2–2HA expression vector, together with empty vector or increasing amounts of HIV1 FLAG–Vpr expression vector
as indicated. Twenty-four hours later cell lysates were prepared and subjected to immunoblotting with anti-HA, anti-FLAG and anti-b-actin antibodies
(C). Quantitation of relative UNG2 degradation for Figure 3C is shown in D. 293T HEK cells were transfected with 1 mg of UNG2–2HA expression
vector, together with empty vector or increasing amounts of HIV1 FLAG–VprR90K expression vector as indicated. Forty-eight hours later cell lysates
were prepared and subjected to immunoblotting with anti-HA, anti-FLAG and anti-b-actin antibodies (E). Quantitation of relative UNG2 degradation
for Figure 3E is shown (F) 293T HEK cells were transfected with 1 mg of UNG2–2HA expression vector, together with empty vector or increasing
amounts of HIV1 FLAG–Vpr expression vector as indicated. Forty-eight hours later cell lysates were prepared and subjected to immunoblotting with
anti-HA, anti-FLAG and anti-b-actin antibodies (G). Quantitation of relative UNG2 degradation for Figure 3G is shown (H).
doi:10.1371/journal.pone.0030939.g003
HIV1 Vpr Enhances Constitutive UNG2 Turnover
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the differences in necrotic cell fractions could not account for the
differences in UNG2 expression. Of note, similar results were seen
with a second non-arresting Vpr mutant, VprR80A (Figure S2).
This mutant has been reported to act as a dominant negative in
G2 arrest assays [5].
High levels of Vpr expression cause accumulation of
phosphorylated UNG2 and redistribution of UNG2 into
the cell nucleus
In our Vpr titration experiments we noticed that when Vpr
expression reached a level that blocked UNG2 degradation, the
doublet representing UNG2 changed from one with a predom-
inant lower molecular weight band to one with a predominant
higher molecular weight band (Figure 3A, C, E and G). The upper
band of the doublet represents a phosphorylated form of UNG2
that has been described previously [31]. We reconfirmed that the
shift seen in our experiments is due to phosphorylation by
phosphatase-treating UNG2 that was immunoprecipitated from
cells transfected with an expression vector for UNG2–2HA. The
higher molecular weight band of the doublet was depleted after
phosphatase treatment (Figure S3). Thus high levels of Vpr caused
a shift from the unphosphorylated form of UNG2 to one with a
higher degree of phosphorylation.
Hagen and colleagues have shown that cyclin-dependent
kinases (CDKs) phosphorylate UNG2 [31]. CDKs are found
largely in the cell nucleus while UNG2 is found in both the nucleus
and the cytoplasm. Our observations thus prompted us to
hypothesize that high levels of Vpr expression may change the
distribution of UNG2 from the cytosol to the nucleus where it can
be phosphorylated.
We repeated the transfections as in the experiments shown in
Figure 3, but separated the cells into nuclear and cytosolic
fractions (Figures 4A and B). The total UNG2 levels matched
those in the whole-cell lysates in Figure 3. As Vpr expression was
increased, the levels of endogenous UNG2 decreased both in the
cytoplasm and in the nucleus (Figure 4A). However, after Vpr
expression was increased further, to the level where UNG2
degradation was blocked, UNG2 accumulated more in the nucleus
than in the cytoplasm. Of note, the cytoplasmic and nuclear lanes
were loaded with extracts from equivalent numbers of cells. The
same patterns were also apparent but more pronounced in cells co-
transfected with expression vectors for UNG2–2HA and Vpr
(Figure 4B). Cells expressing high levels of Vpr clearly accumu-
lated UNG2–2HA in the nucleus but not in the cytoplasm.
How do UNG2 levels respond to HIV1 infection? In order to
relate our titrations to the levels of Vpr expressed by HIV1, we
infected HEK 293T cells with vesicular stomatitis G-protein
pseudotyped HIV1 and measured UNG2 levels. We used either
virus with a deletion in the vpr gene (vpr(–)) or wild-type virus. Both
virus types had a green fluorescent protein gene in place of the nef
sequence that did not overlap the 39 U3 region. We infected the
cells at a multiplicity of one. At 24 and 48 hours post transfection,
we harvested sets of cultures that were uninfected, infected with
vpr(–) virus or infected with wild-type virus. A portion of these cells
were reserved, at 24 hours post infection, for flow cytometry to
determine the percentage of infected cells. The remainder of the
cells were fractionated to determine the subcellular distribution of
endogenous UNG2, p24
gag and Vpr. Tubulin and histone H3
were used as fractionation and loading controls.
As early as 24 hours after infection, UNG2 was not detectable
in either cell fraction (Figure 4C). The two types of infection were
closely matched; both showed equivalent p24
gag levels and GFP
was detectable in 86% of the vpr(–) virus- and 79% of the wild-type
virus-infected cells (Figure S4). While the number of infected cells
was not identical, the difference in infection could not account for
the detected difference in UNG2 levels.
Attenuation of ubiquitin ligase function promotes UNG2
redistribution that is further enhanced by Vpr
High levels of Vpr expression failed to target UNG2 for
destruction but instead promoted its accumulation in the cell
nucleus. We next tested whether nuclear accumulation of UNG2
results from active translocation by Vpr or is a consequence of
increased UNG2 stability resulting from decreased ubiquitin
ligase action on this protein. To distinguish between these
possibilities, we examined whether interfering with UNG2
ubiquitination in the absence of Vpr would affect its subcellular
distribution. We perturbed UNG2 degradation by expressing
K48R ubiquitin to reduce K48 polyubiquitination, by depleting
components of the ubiquitin ligase complex with expression
vectors for DDB1- or DCAF1-directed shRNA, by disrupting
formation of the complex by over-expressing its components
using DDB1 or DCAF1 expression plasmids or by inhibiting the
activity of the complex with a dominant negative mutant of
Cul4A. We transfected HEK 293T cells with UNG2–2HA
expression vector together with empty expression vector and
expression constructs for wild-type ubiquitin, K48R ubiquitin,
expression vectors for DDB1- or DCAF1-directed shRNA,
DDB1, DCAF1, dominant negative Cul1 or dominant negative
Cul4A (Figure 5A). As a positive control for UNG2 nuclear
translocation we co-transfected another culture with expression
vectors for both UNG2–2HA and Vpr.
Overproduction of wild-type ubiquitin and dominant negative
Cul1, as expected, did not alter the levels or the distribution of
UNG2 detectably (Figure 5A). Expression of DCAF1-directed
shRNA increased overall levels of UNG2–2HA but did not change
the nuclear to cytoplasmic distribution ratio or phosphorylation
status noticeably. Exogenous expression of K48R ubiquitin,
DDB1-directed shRNA, DDB1, DCAF1, and dominant negative
Cul4A all led to varying increases both in total and nuclear UNG2
levels (Figure 5A). These results show that interfering with UNG2
degradation by expressing K48R ubiquitin or by altering the
composition/activity of the CRL4
DCAF1 ubiquitin ligase complex
is sufficient to increase relative levels of UNG2 in the cell nucleus.
We observed a similar redistribution of UNG2 into the cell nucleus
when we treated UNG2–2HA expressing cells with the protea-
some inhibitor MG132 (Figure 5B). Thus, Vpr is not required per se
for the redistribution of UNG2. However it is important to note
that inhibition of the normal UNG2 turnover does not result in
complete nuclear translocation like high Vpr expression does
(compare the cytosolic fractions of UbK48R, DDB1 shRNA,
DDB1, DCAF1, and DN Cul4A to the cytosolic fraction of the
Flag–Vpr-transfected samples).
Nuclear UNG2 accumulation in the presence of high Vpr levels
cannot be explained entirely by diminished UNG2 degradation.
Importantly these data, showing that either high expression of Vpr
or perturbation of the ubiquitin ligase complex causes UNG2
accumulation in the nucleus, indicate that the two functions are
linked in a common pathway. This reinforces our finding that high
levels of Vpr block constitutive DCAF1-mediated turnover of
UNG2. Altogether, our data support a model in which UNG2 is
degraded by CRL4
DCAF1 via its interaction with DCAF1 in the
absence of Vpr (Figure 6A). Vpr enhances the degradation by
boosting the interaction between DCAF1 and UNG2 (Figure 6B)
and can both interfere with degradation and possibly facilitate
nuclear import at high levels (Figure 6C).
HIV1 Vpr Enhances Constitutive UNG2 Turnover
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30939Figure 4. HIV1 Vpr-mediated degradation and subcellular redistribution of UNG2 are dose-dependent. 293T HEK cell cultures were
transfected with empty vector alone and together with increasing quantities of HIV1 FLAG–Vpr expression vector as indicated. 48 hours after
transfection nuclear and cytoplasmic fractions were prepared and analyzed by immunoblotting with antibodies specific for UNG2, FLAG epitope tag
(FLAG–Vpr), a tubulin (cytoplasmic fraction control) and Histone H3 (nuclear fraction control) (A). 293T cultures were transfected with 1 mg of UNG2–
HA expression vector alone, together with increasing quantities of HIV1 FLAG–Vpr expression vector as indicated. 48 hours after transfection nuclear
and cytoplasmic fractions were prepared. Immunoblotting with anti-HA (UNG2–2HA), anti-FLAG (FLAG–Vpr), anti-a tubulin (cytoplasmic fraction
control) and anti-Histone H3 (nuclear fraction control) antibodies was used to determine relative quantities of the respective protein that were
present in the fractions (B). HEK 293T cells, either untransfected (left) or transfected with 1 mg of UNG2–2HA expression vector and 3 mg of empty
vector (C, right) were mock-infected (none), infected with vpr(–), env(–), VSV-G-pseudotyped virus (vpr(–)) or with wild-type, env(–), VSV-G-
pseudotyped virus (wild-type).
doi:10.1371/journal.pone.0030939.g004
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of UNG2 degradation
Vpr-mediated G2 cell cycle arrest depends on CRL4
DCAF1
[1,2,3,4,5,6,7], but it is not linked to Vpr-mediated UNG2
degradation [34]. The degradation target responsible for G2 cell
cycle arrest has not been identified. We therefore sought to
determine whether this unknown target behaves like UNG2 in
response to Vpr expression. In devising strategies to identify the
cellular protein that is ubiquitinated in response to Vpr expression
to trigger arrest, it will be important to determine whether it can
be protected by Vpr over-expression. In order to test whether Vpr
expression levels influence the efficiency of Vpr-mediated G2
arrest, we transfected HEK 293T cells with 175 ng of laminC–
GFP expression vector, to allow identification of transfected cells,
and a mix of empty expression vector and increasing quantities of
Vpr expression vector. We harvested the cells 48 hours after
transfection and measured cellular DNA content using flow
cytometry. First, the fraction of cells with DNA content indicative
of G2/M (4n) increased with the amount of Vpr expression vector
that was transfected (Figure 7A and B). This fraction of cells in
G2/M reached a plateau and then decreased as levels of Vpr
expression were further increased.
Thus, Vpr levels control the efficiency with which Vpr causes
G2 arrest in a pattern that parallels Vpr-mediated UNG2
degradation (compare Figure 7B to Figures 3A and 3C). It is
therefore likely that Vpr interacts with the target protein
responsible for G2 cell cycle arrest phenotype and the ubiquitin
ligase in a manner similar to that with which it interacts with
UNG2. Specifically, low levels of Vpr aid ubiquitin ligase function,
but high levels interfere with this process.
Discussion
In work described here, we showed for the first time that
DCAF1 and the ubiquitin ligase complex that includes DDB1 and
Cul4 play important roles in the turnover of UNG2 and SMUG1
in the absence of Vpr. Depletion of DCAF1 using shRNA
increased the levels of both in the presence and absence of Vpr.
Further, modifications to the composition of the ubiquitin ligase
also increased cellular UNG2 and SMUG1 concentrations
(Figure 1). Importantly, we were able to co-immunoprecipitate
Figure 5. HEK 293T cells were transfected with 1 mg of UNG2–2HA expression vector together with the indicated expression
vectors. Forty-eight hours after transfection nuclear and cytoplasmic fractions were prepared. The composition of these fractions was characterized
by immunoblotting with HA-, DDB1-,a tubulin- or anti-Histone H3-specific antibodies (A). 293T cells were transfected with UNG2–2HA expression
vector, together with empty vector, or expression vector for wild type HIV1 FLAG–Vpr (3 mg). MG132 (12.5 mM) or DMSO (vehicle control) were added
24 hours after transfection. 16 hours later nuclear and cytoplasmic fractions were prepared and characterized by immunoblotting with anti-HA, anti-
FLAG, anti-a tubulin (cytoplasmic fraction control) and anti-Histone H3 (nuclear fraction control) antibodies (B).
doi:10.1371/journal.pone.0030939.g005
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same protein complex.
Recent work by Ahn et al. showed that in an in vitro assembly of
CRL4
DCAF1 components that had been produced in E. coli, UNG2
ubiquitination was enhanced in the presence of Vpr [28].
Interestingly however, lower levels of ubiquitinated UNG2 were
also apparent in their samples containing CRL4
DCAF1 in the
absence of Vpr. This supports our results indicating that UNG2 is
normally targeted by this complex. The work by Ahn also showed
that DCAF1 is important for UNG2 degradation but curiously
they saw no depletion of exogenous UNG2 in cells unless they co-
transfected exogenous DCAF1. This could, of course, be due to
the relative quantity of Vpr that they were producing in those cells.
UNG2 levels have been shown to decline after S-phase to then
be restored after mitosis. In our experiments we examined UNG2
levels in asynchronous cell populations; our work however sets the
stage for determining whether the CRL4
DCAF1 ubiquitin ligase
complex is responsible for this synchronized turnover. UNG2 and
Merlin are the only confirmed substrates for the CRL4 complex.
Merlin degradation occurs in response to serum stimulation as
cells re-enter the cell cycle at G1 while UNG2 degradation occurs
just before mitosis. It remains to be seen whether other cellular
proteins act to specifically modify, rather than enable, the
targeting of the ubiquitin ligase. For example, do cells express
Vpr-like proteins that determine whether or when UNG2, Merlin
or other proteins will be targeted for ubiquitination?
Expression of HIV1 Vpr enhances UNG2 degradation [18].
Our observations that UNG2 can assemble with the ubiquitin
ligase complex in the absence of Vpr and that UNG2 levels can be
increased by depleting DCAF1 show that Vpr, rather than being
required for the interaction, enhances its outcome. The augmen-
tation could be in the form of more efficient ubiquitin ligase
activity. Our data however, showing that we can co-immunopre-
cipitate endogenously-expressed components of the ubiquitin
ligase complex with UNG2 more efficiently from cultures that
co-express Vpr indicate that this protein is likely stabilizing the
assembly of UNG2 with the ubiquitin ligase complex (Figure 2).
This model is supported by a number of studies that strongly
suggest that Vpr can engage both UNG2 and the ubiquitin ligase
complex individually. Yeast two-hybrid experiments showed that
Vpr and UNG2 [19] or DCAF1 [7] can assemble in the absence of
other mammalian proteins. Other work highlighted the Vpr
mutant W54R which displays a weakened capacity to engage
UNG2 and a UNG2 motif (WXXF) that is required for Vpr
binding [34,36]. Studies where Vpr, DCAF1 and UNG2 were
mixed in vitro and subjected to analytical size exclusion
chromatography showed that when DCAF1 WD40 domain, Vpr
residues 1–79 and UNG2 residues 99–313 were mixed, all three
eluted in the same fraction whereas the separate components
eluted in different volumes [28]. All of these observations support
the formation of a tri-molecular UNG2NVprNDCAF1 complex,
although we cannot rule out the possibility that Vpr engages
multiple partners on the same complex.
The changes in UNG2 degradation in response to different Vpr
levels are also consistent with a model in which Vpr enhances the
interaction between UNG2 and the ubiquitin ligase complex. If
Vpr can engage both UNG2 and DCAF1 it is conceivable that
Vpr can engage either protein to help facilitate the interaction.
After sites on both are saturated, in this scenario, it is conceivable
that Vpr interferes with assembly of UNG2 with the ubiquitin
ligase complex. It is less likely, if Vpr were enhancing ubiquitin
ligase activity that the function would first increase and then
decrease. Further, it appears that decreasing the ubiquitin ligase
function allows UNG2 to accumulate in the cell nucleus, but not to
the same extent as it does in the presence of high concentrations of
Vpr. It is not clear how Vpr promotes the additional increase in
Figure 6. Model for HIV1 Vpr-mediated degradation. In the absence of HIV1 Vpr expression, UNG2 engages DCAF1, is ubiquitinated and thus
marked for proteasomal degradation (A). In the presence of HIV1 Vpr, CRL4
DCAF1-mediated ubiquitination of UNG2 is increased because Vpr enhances
the interaction between UNG2 and DCAF1 (B). In the presence of high HIV1 Vpr levels, UNG2 degradation is no longer increased and instead, UNG2
accumulates in the cell nucleus (C).
doi:10.1371/journal.pone.0030939.g006
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nuclear import signal(s) to this complex [37,38].
Vpr is a relatively small protein and the amino acid residues that
have been associated with UNG2 binding (W54) and DCAF1
binding (Q65) are close together. It will be interesting to determine
exactly how the proteins assemble. Vpr has been shown to
multimerize [39,40] and could therefore act as a multimer to
enhance protein degradation.
The parallels that we observed between the patterns in Vpr-
mediated UNG2 degradation and cell cycle arrest suggest that the
findings presented here will have relevance to other targets of Vpr
action. The protein target for Vpr-mediated cell cycle arrest
remains to be identified. In designing a strategy to discover this
cellular protein partner our results show that we must consider the
possibility that it is already a target for the CRL4
DCAF1 ubiquitin
ligase complex and that this association could be broken if Vpr is
present at high levels. Further, over-expression of Vpr could cause
depletion of the target in one subcellular compartment and
accumulation in another. Finally, our observations stress the
importance of evaluating Vpr-mediated effects at multiple
expression levels.
Together the observations described in this work extend our
knowledge about UNG2 turnover and demonstrate that Vpr acts
in cells to enhance this process. Importantly, these studies also
emphasize that it is crucial to test a range of Vpr concentrations
during the investigation of Vpr functions because they may only
occur at specific expression levels. It thus sets the stage for further
studies to determine in greater detail how UNG2 degradation is
regulated and also provides important new information regarding
the control of protein degradation by HIV1 Vpr that will aid in the
identification of targets that are critical for HIV1 replication and
pathogenesis.
Materials and Methods
Cell cultures
293T HEK cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Hyclone, Mediatech Inc) supplemented with
10% fetal bovine serum (FBS), 100 U/ml of penicillin, 100 mg/ml
of streptomycin and 2 mM L-glutamine at 37uC with 5% CO2.
Harvesting of cell cultures
In order to assure that we were sampling the entire cell
population in our assays we harvested all of the cells in each well.
Of note however we found no noticeable increase in non-adherent
cells with any of the treatment conditions. This was paralleled by
the necrotic cell staining shown in Figures S1 and S2.
Plasmids and cell transfection
The plasmids pcDNA3.1(–)HIV1 FLAG–huVpr, pcDNA3.1(–)
DNCul4A, pSport6 FLAG–DCAF1, pSM2c DDB1-directed
shRNA and pSM2c DCAF1-directed shRNA were described
previously [1]. In order to improve detection sensitivity for UNG2,
the corresponding coding sequence was sub-cloned from
pcDNA3.1(+)UNG2–HA (provided by Dr. Ned Landau) into
pcDNA3.1(–) with the addition of a second HA tag. The
Figure 7. The pattern of Vpr-induced cell cycle arrest mirrors that of Vpr-mediated UNG2 depletion. 293T HEK cells were transfected
with empty vector or increasing amounts of HIV1 FLAG–Vpr expression vector as indicated. Total plasmid DNA in each transfection was kept constant
by addition of empty vector. The cells in each sample were co-transfected with 175 ng of laminC2GFP to allow identification of nuclei from
transfected cells by flow cytometry. The cell nuclei were isolated 48 hours after transfection, treated with RNaseA and stained with propidium iodide.
The DNA content was determined by flow cytometry (A). Panel B shows the (G2+M)/G1 ratios for comparison.
doi:10.1371/journal.pone.0030939.g007
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provided by Dr. Zhen-Qiang Pan. The expression vector for T7-
tagged DDB1 plasmid was provided by Dr. Pradip Raychaudhuri.
The expression vectors for wild-type ubiquitin and the non-
branching K48R mutant were from Dr. Ron Kopito.
Cells were transfected using a standard calcium phosphate
protocol. When proteasome inhibitor was used, MG132 (12.5 mM)
was added 24 hours after transfection and cells were lysed
16 hours later.
Immunoprecipitation
To determine whether UNG2 co-immunoprecipitates with
DCAF1, cells were lysed in 1.0 ml of cold ELB buffer (50 mm
HEPES, pH 7.3, 400 mm NaCl, 0.2% Nonidet P-40, 5 mm
EDTA, 0.5 mm dithiothreitol, and Complete
TM protease inhibitor
mixture (Roche Applied Science, as per instructions)). The lysates
were cleared by centrifugation. The supernatant was incubated
with anti-FLAG M2 agarose resin (Sigma-Aldrich). The beads
were subsequently washed three times in 1 ml of lysis buffer before
bound proteins were eluted with 200 mg/ml of FLAG peptide
(Sigma-Aldrich). Eluted proteins were analyzed by immunoblot
with anti-HA antibody.
To determine whether Vpr enhances the interaction between
UNG2 and the CRL4
DCAF1 ubiquitin ligase complex, the cells
were lysed in 1.0 ml of cold ELB buffer and subjected to
immunoprecipitation with anti-HA-agarose beads. The beads
were subsequently washed three times in 1 ml of lysis buffer before
bound proteins were eluted with 200 mg/ml of HA peptide
(Sigma-Aldrich). Western blots of the pre- and post-immunopre-
cipitation samples were probed for DDB1, DCAF1, UNG2–2HA
and HIV1 FLAG–Vpr.
Western blot analysis
Analyses were done following standard western blotting
procedures. The primary antibodies used were: anti-FLAG M2
(F1804, Sigma-Aldrich), anti-HA monoclonal 12CA5 (Roche),
anti-DDB1 (Clone ZMD.05, Invitrogen), anti-DCAF1 (a gift from
Dr. Ling-Jun Zhao), anti-UNG antibody (a gift from Dr. Geir
Slupphaug), anti-a-Tubulin monoclonal (N-356, Amersham), anti-
Histone 3 polyclonal (06-755, Upstate Biotech), and anti-b-actin
monoclonal (A5441, Sigma-Aldrich).
Subcellular fractionation
Cell fractionation was carried out using a protocol described
previously [41]. Briefly, cells were suspended in Buffer B (10 mM
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl and Complete
TM
protease inhibitor cocktail (Roche)) and incubated on ice for
10 min. subsequently cells were lysed by adding 10% NP-40
during brief vortex mixing to a final concentration of 0.04% NP-
40. Whole cell lysates were transferred onto 1 ml, 1 M sucrose
cushions. After centrifugation at 20006g for 10 min, the layer
above the interface with the cushion was collected as the
cytoplasmic fraction. Nuclei, pelleted below the sucrose cushion,
were washed once with Buffer B and then lysed in Laemmli buffer.
The volume of the nuclear fraction was adjusted so that gels could
be loaded with nuclear and cytoplasmic extracts from equivalent
numbers of cells.
Infection/Fractionation
Molecular clones of HIV-1 lacking the capacity to encode Env
or both Env and Vpr and encoding GFP in place of N-terminal nef
sequences were transfected into 293T cells together with an
expression vector for VSV-G. Cell-free supernatants were
harvested from these cells 48 hours after transfection. These
supernatants were used to infect 293T cells at an estimated
multiplicity of infection of one. Cells were harvested 24 and
48 hours after infection. At 24 hours some of the cells were
reserved for flow cytometry to re-confirm equivalent infections by
detection of virus-encoded GFP (Figure S4). The remainder of the
cells was fractionated as described above. The fractions were then
analyzed by western blotting for UNG2, for tubulin as a
cytoplasmic fraction loading and fractionation control, for histone
H3 as a nuclear fraction loading and fractionation control, for
p24
gag as another control for equivalent infection, and for Vpr, to
reconfirm Vpr expression in the corresponding samples.
Necrosis assay
Cells were harvested 48 hours after cultures were transfected
with pcDNA3.1(–) and/or pcDNA3.1(–) HIV1 FLAG–huVpr,
HIV1 FLAG–huVprR90K or pcDNA3.1(–) HIV1 FLAG–
huVprR80A in the amounts and combinations indicated in
Figures S1 and S2. All of the media and washes were collected
to assure that all live and dead cells were retained. Cells were
trypsinized, washed and then exposed to propidium iodide in PBS
(10 mg/ml) for 20 minutes before the fraction of propidium iodide-
stained cells was determined using flow cytometry. Cells used as
positive staining controls were fixed in 2% formaldehyde for
20 minutes before staining.
Cell cycle analysis
293T HEK cells were transfected with empty vector or
increasing quantities of HIV1 FLAG–Vpr expression vector.
Total plasmid DNA was kept constant by adding empty vector.
Each transfection contained 0.17 mg laminC–GFP to identify
nuclei of transfected cells. At 48 hours post-transfection, cell nuclei
were isolated and treated with RNaseA and propidium iodide as
described previously [1]. DNA content was measured by flow
cytometry.
Supporting Information
Figure S1 The fraction of necrotic cells is not linked to
Vpr expression at 48 hours post-transfection. Cells were
harvested forty eight hours after transfection with pcDNA3.1(–)
and/or pcDNA3.1(–) HIV1 FLAG–huVprR90K (A) or
pcDNA3.1(–) HIV1 FLAG–huVpr (B) in the amounts and
combinations indicated. All cells, adherent or floating were
included in the analysis. Cultures were trypsinized, washed and
then half of the cells were exposed to propidium iodide in PBS
(10 mg/ml) for 20 minutes before the fraction of propidium iodide-
stained cells was determined using flow cytometry. The other half
was analyzed for protein content (Figure 3 E-H). Cells used as
positive staining controls were fixed in 2% formaldehyde for
20 minutes before staining. A second set of cultures was
transfected with pcDNA3.1(–) and/or pcDNA3.1(–) HIV1
FLAG–huVprR90K (C) or pcDNA3.1(–) HIV1 FLAG–huVpr
(D), as indicated, together with 0.175 mg/culture of GFP
expression vector to allow comparison between transfected and
untransfected cell populations. These cultures were treated and
analyzed like those in panels A and B above.
(TIF)
Figure S2 HIV1 Vpr R80A-mediated UNG2 degradation
is dose-dependent and Expression of Vpr R80A does not
adversely impact cell viability by 48 hours after trans-
fection. 293T HEK cells were transfected with empty vector or
increasing amounts of HIV1 FLAG–Vpr R80A expression vector
as indicated. 48 hours later the cells were lysed and the expression
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determined by immunoblotting (A). Quantitation of relative
UNG2–2HA degradation was plotted (B). Cells transfected as
indicated, were analyzed for propidium iodide staining as in
Figure S1, panels C and D (C).
(TIF)
Figure S3 Phosphatase treatment eliminates the slow-
migrating form of UNG2. 293T HEK cultures were
transfected with expression vectors for UNG2–2HA, the K48R
ubiquitin mutant together with empty vector or expression vector
for HIV1 FLAG–Vpr. At 48 hours post-transfection, the cells were
harvested and UNG2–2HA was immunoprecipitated from the
lysates with anti-HA agarose beads. The beads were divided into
two samples. One sample was treated with calf intestinal
phosphatase and the other was incubated in buffer alone. The
bound proteins were eluted with HA peptide and immunoblotted
for UNG2–2HA.
(TIF)
Figure S4 The infection efficiency of vpr(–) virus was
similar to that of wild-type virus in the experiment
shown in Figure 4C. Cells reserved at 24 hours post-infection
were fixed with formaldehyde and analyzed for GFP fluorescence
as in indicator of infection with the GFP-expressing viruses.
(TIF)
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